Effectiveness of Discriminant Analysis of Serum CA 19-9 and Elastase 1 in Diagnosis of Pancreatic Carcinoma

Yamamura, Hisako; Tatsuta, Masaharu; Ito, Michiko; Noguchi, Sanai; Okuda, Shujiro; Yoshida, Mototsugu

doi:10.1097/00006676-198908000-00002

Cited by 12 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum E1 had sensitivity of 61.5%, specificity of 75.3% and overall accuracy of 71.2% for the diagnosis of pancreatic cancer, which agreed with results reported by other authors 2,6,7,9 . In the meantime, the sensitivity, specificity and overall accuracy of CA19‐9 was 71.8%, 73.1% and 72.7%, respectively.…”

Section: Discussionsupporting

confidence: 89%

“…Most authors agree that tumors of the pancreatic head could elevate serum E1 more readily than of the body and/or tail, based on the hypothesis that tumors at the proximal end of the pancreatic duct are prone to obstruct the pancreatic duct more extensively, 2,5,9,10 which again was proved by this study. In addition we showed that tumors with smaller size (≤3 cm) had a higher level of serum E1 than those with larger size (>6 cm), which had also been reported by other researchers 2,6,9 . For this reason E1 has been viewed as a promising marker to detect early pancreatic carcinoma, which might be helpful to improve the resection rate of pancreatic cancer, because tumors with smaller size usually have a greater chance to be excised successfully.…”

Section: Discussionsupporting

confidence: 84%

“…The normal value of serum E1 indicated by the assay kit is 4 ng/mL, and a range of 3-5 ng/mL is accommodated by most authors. 2,[4][5][6] It could also be as high as 7.396 ng/mL. 7 The present study is the first, according to our knowledge, to establish the cutoff value of serum E1 in Chinese adults to be 4.36 ng/mL by the method of ROC curve.…”

Section: Discussionmentioning

confidence: 87%

“…In this study DA had better diagnostic effectiveness as compared with combined assay and the test of E1 and CA19‐9 alone in terms of overall accuracy. Our study indicated that assay of multiple tumor markers with implementation of appropriate statistical methods can improve the diagnostic level of pancreatic cancer, and this is important given the fact that there is no better single tumor marker available so far 6–9 …”

Section: Discussionmentioning

confidence: 88%

“…The normal value of serum E1 indicated by the assay kit is 4 ng/mL, and a range of 3–5 ng/mL is accommodated by most authors 2,4–6 . It could also be as high as 7.396 ng/mL 7 .…”

Section: Discussionmentioning

confidence: 98%

See 4 more Smart Citations

Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer

Qian

Deng

et al. 2006

Chinese Journal of Digestive Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 88%

“…The normal value of serum E1 indicated by the assay kit is 4 ng/mL, and a range of 3–5 ng/mL is accommodated by most authors 2,4–6 . It could also be as high as 7.396 ng/mL 7 .…”

Section: Discussionmentioning

confidence: 98%

See 3 more Smart Citations

Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer

Qian

Deng

et al. 2006

Chinese Journal of Digestive Diseases

View full text Add to dashboard Cite

show abstract

A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/ WGA) assessed in combination with CA 19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer

Parker

Makin

Ching

et al. 1992

Cancer

View full text Add to dashboard Cite

Background. Mucus glycoproteins are often present in the sera of patients with pancreatic cancer, and their detection and quantification can be used in serologic diagnosis. Methods. A novel enzyme‐linked “sandwich” assay (CAM 17.1/WGA) has been developed in which a lectin, wheat germ agglutinin (WGA), is bound to the solid phase to capture serum glycoproteins, and after addition of test sera, a monoclonal antimucin antibody (CAM 17.1) and peroxidase‐tagged second antibody are used as a detection system. Results. The test has been applied to sera from 79 patients with pancreatic cancer and 120 controls. The CAM 17.1/WGA assay alone had a sensitivity of 78% and specificity of 76% in the diagnosis of pancreatic cancer. Combination of the CAM 17.1/WGA test with a previously described peanut lectin binding assay (PNA/ELLA) provided a sensitivity of 92% and specificity of 70%, whereas combination of the CAM 17.1/WGA assay with the CA 19‐9 radioimmunoassay had a sensitivity of 85% and specificity of 76%. Combination of all three tests had a sensitivity of 94% and specificity of 66%. In nonjaundiced patients, the combination of CAM 17.1/WGA and PNA/ELLA had a sensitivity of 93% and specificity of 79% in the diagnosis of pancreatic cancer. Conclusions. This new test adds significantly to the armamentarium of serologic tests for pancreatic cancer. These tests are particularly effective when used in combination to detect different mucin‐borne carbohydrate antigens. They deserve more widespread use, particularly in examining nonjaundiced patients with unexplained abdominal pain or weight loss.

show abstract

Clinical usefulness of computer-assisted diagnosis using combination assay of tumor markers for pancreatic carcinoma

Saito

Taguchi

Nishimura

et al. 1993

Cancer

View full text Add to dashboard Cite

Background. There has been extensive use of serum tumor markers in diagnosing pancreatic adenocarcinoma. There is no tumor marker, however, that alone has sufficient diagnostic accuracy. It is necessary to know which combination of tumor markers should be used to detect pancreatic cancer, with respect to clinical usefulness and cost effectiveness. Methods. Serum levels of 17 kinds of tumor markers were determined in 145 patients and 40 healthy volunteers. Thirty‐five patients with proven pancreatic adenocarcinoma, and 32 with benign pancreatobiliary disease (14 chronic pancreatitis and 18 biliary stones) were selected. For analysis of the usefulness of each tumor marker to differentiate these two groups, scatterplot and relative operating characteristic (ROC) analyses were used. A multivariate discriminant system to differentiate these two groups was developed using stepwise discriminant analysis by backward elimination selection. Results. The significance of each tumor marker varied according to the tumor volume. By ROC analysis, the markers were divided into four subgroups according to their usefulness in discriminating pancreatic adenocarcinoma from benign pancreatobiliary disease. A discriminant system consisting of two different discriminant functions using nine tumor markers (CA 19–9, DUPAN‐2, TPA, elastase‐1, lipase, amylase, γ‐glutamyl transpeptidase, alkaline phosphatase, and lactate dehydrogenase) was developed and designated CAMPAS‐P; it could differentiate between all 35 cases of pancreatic adenocarcinoma and 32 cases of benign pancreatobiliary disease. On the other hand, CAMPAS‐P showed a low positive rate in pancreatic tumors of unusual histologic type, and poor organ‐specific diagnostic ability in various digestive organ malignancies. Conclusions. CAMPAS‐P may be very useful for differential diagnosis between pancreatic adenocarcinoma and benign pancreatobiliary disease.

show abstract

Effectiveness of Discriminant Analysis of Serum CA 19-9 and Elastase 1 in Diagnosis of Pancreatic Carcinoma

Cited by 12 publications

References 0 publications

Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer

Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer

A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/ WGA) assessed in combination with CA 19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer

Clinical usefulness of computer-assisted diagnosis using combination assay of tumor markers for pancreatic carcinoma

Contact Info

Product

Resources

About